1,162,986 Shares in Roivant Sciences Ltd. (NASDAQ:ROIV) Bought by Gilder Gagnon Howe & Co. LLC

Gilder Gagnon Howe & Co. LLC acquired a new position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 1,162,986 shares of the company's stock, valued at approximately $13,758,000. Gilder Gagnon Howe & Co. LLC owned approximately 0.16% of Roivant Sciences at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Russell Investments Group Ltd. boosted its stake in Roivant Sciences by 478.6% during the fourth quarter. Russell Investments Group Ltd. now owns 2,355 shares of the company's stock worth $28,000 after acquiring an additional 1,948 shares in the last quarter. Aster Capital Management DIFC Ltd bought a new stake in Roivant Sciences during the fourth quarter worth about $39,000. GAMMA Investing LLC boosted its stake in Roivant Sciences by 57.0% during the fourth quarter. GAMMA Investing LLC now owns 3,548 shares of the company's stock worth $42,000 after acquiring an additional 1,288 shares in the last quarter. PNC Financial Services Group Inc. boosted its stake in Roivant Sciences by 27.0% during the fourth quarter. PNC Financial Services Group Inc. now owns 7,079 shares of the company's stock worth $84,000 after acquiring an additional 1,507 shares in the last quarter. Finally, Wells Fargo & Company MN boosted its stake in Roivant Sciences by 84.1% during the fourth quarter. Wells Fargo & Company MN now owns 7,501 shares of the company's stock worth $89,000 after acquiring an additional 3,426 shares in the last quarter. Institutional investors own 64.76% of the company's stock.

Roivant Sciences Stock Up 1.6 %

Roivant Sciences stock traded up $0.18 during trading hours on Monday, hitting $11.19. The stock had a trading volume of 8,301,459 shares, compared to its average volume of 5,473,407. The stock has a market capitalization of $7.98 billion, a P/E ratio of -74.60 and a beta of 1.25. Roivant Sciences Ltd. has a 12-month low of $8.73 and a 12-month high of $13.06. The stock's 50-day moving average price is $10.35 and its 200-day moving average price is $11.14.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last released its quarterly earnings data on Monday, February 10th. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. On average, research analysts expect that Roivant Sciences Ltd. will post -0.92 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on ROIV. Cantor Fitzgerald raised shares of Roivant Sciences to a "strong-buy" rating in a report on Tuesday, March 4th. HC Wainwright reaffirmed a "buy" rating and issued a $18.00 target price on shares of Roivant Sciences in a report on Monday, April 21st.

Insider Activity

In other news, COO Eric Venker sold 218,041 shares of the business's stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $10.42, for a total transaction of $2,271,987.22. Following the completion of the transaction, the chief operating officer now directly owns 896,869 shares of the company's stock, valued at $9,345,374.98. The trade was a 19.56 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Rakhi Kumar sold 227,500 shares of the business's stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $10.43, for a total transaction of $2,372,825.00. Following the transaction, the chief accounting officer now directly owns 163,264 shares of the company's stock, valued at $1,702,843.52. The trade was a 58.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,395,541 shares of company stock valued at $14,922,538 over the last three months. Insiders own 7.90% of the company's stock.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.